Compile Data Set for Download or QSAR
Report error Found 94 Enz. Inhib. hit(s) with all data for entry = 9165
TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446469(US10669271, Example 22 | (S)-1-((7-cyano-2-(3̸...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446456(US10669271, Example 9 | (R)-1-((7-cyano-2-(3′...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446457(US10669271, Example 10 | (R)-1-((7-cyano-2-(3̸...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446458(US10669271, Example 11 | (R)-1-((7-cyano-2-(3̸...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446459(US10669271, Example 12 | (R)-1-((7-cyano-2-(3̸...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446460(US10669271, Example 13 | (R)-1-((7-cyano-2-(3̸...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446461(US10669271, Example 14 | (R)-1-((7-cyano-2-(3̸...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446462(US10669271, Example 15 | (R)-1-((7-cyano-2-(3̸...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446464(US10669271, Example 17 | US10669271, Example 20 | ...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446465(US10669271, Example 18 | US10669271, Example 21 | ...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446463(US10669271, Example 16 | US10669271, Example 19 | ...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446464(US10669271, Example 17 | US10669271, Example 20 | ...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446465(US10669271, Example 18 | US10669271, Example 21 | ...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446463(US10669271, Example 16 | US10669271, Example 19 | ...)
Affinity DataEC50: <10nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446470(US10669271, Example 23 | (S)-1-((7-cyano-2-(3̸...)
Affinity DataEC50: <10nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446471(US10669271, Example 24 | (R)-1-((7-cyano-2-(3̸...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446472(US10669271, Example 25 | (R)-1-((7-cyano-2-(3̸...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446473(US10669271, Example 26 | (R)-1-((7-cyano-2-(3̸...)
Affinity DataEC50: <10nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446474(US10669271, Example 27 | (R)-3-(1-((7-cyano-2-(3&#...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446475(US10669271, Example 28 | (R)-1-((7-cyano-2-(3̸...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446476(US10669271, Example 29 | (R)-1-((2-(3′-(2-am...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446477(US10669271, Example 30 | (R)-1-((7-cyano-2-(3̸...)
Affinity DataEC50: <10nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446478(US10669271, Example 31 | (S)-1-((7-cyano-2-(3̸...)
Affinity DataEC50: <10nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446479(US10669271, Example 32 | (R)-1-((7-cyano-2-(3̸...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446453(US10669271, Example 6 | US10669271, Example 33 | (...)
Affinity DataEC50: <10nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446481(US10669271, Example 34 | (R)-1-((7-cyano-2-(3̸...)
Affinity DataEC50: <10nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446452(US10669271, Example 5 | (S)-1-((7-cyano-2-(3′...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446448(US10669271, Example 1 | (R)-1-((7-cyano-2-(3′...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446450(US10669271, Example 3 | (S)-1-((7-cyano-2-(3′...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446455(US10669271, Example 8 | (R)-1-((7-cyano-2-(3′...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446454(US10669271, Example 7 | (R)-1-((7-cyano-2-(3′...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446451(US10669271, Example 4 | (S)-1-((7-cyano-2-(3′...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446453(US10669271, Example 6 | US10669271, Example 33 | (...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

TargetNuclear factor NF-kappa-B p105 subunit(Human)
Incyte

US Patent
LigandPNGBDBM446449(US10669271, Example 2 | (R)-1-((7-cyano-2-(3′...)
Affinity DataEC50:  55nMAssay Description:PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM446475(US10669271, Example 28 | (R)-1-((7-cyano-2-(3̸...)
Affinity DataIC50: 10nMAssay Description:The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM446476(US10669271, Example 29 | (R)-1-((2-(3′-(2-am...)
Affinity DataIC50: 10nMAssay Description:U2OS/PD-L1 cells (DiscoveRx Corporation) were maintained in McCoy's 5A medium with addition of 10% FBS, 0.25 μg/ml Puromycin. After removing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM446474(US10669271, Example 27 | (R)-3-(1-((7-cyano-2-(3&#...)
Affinity DataIC50: 10nMAssay Description:The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM446451(US10669271, Example 4 | (S)-1-((7-cyano-2-(3′...)
Affinity DataIC50: 10nMAssay Description:The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM446473(US10669271, Example 26 | (R)-1-((7-cyano-2-(3̸...)
Affinity DataIC50: 10nMAssay Description:The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM446451(US10669271, Example 4 | (S)-1-((7-cyano-2-(3′...)
Affinity DataIC50: 10nMAssay Description:U2OS/PD-L1 cells (DiscoveRx Corporation) were maintained in McCoy's 5A medium with addition of 10% FBS, 0.25 μg/ml Puromycin. After removing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM446472(US10669271, Example 25 | (R)-1-((7-cyano-2-(3̸...)
Affinity DataIC50: 10nMAssay Description:The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM446471(US10669271, Example 24 | (R)-1-((7-cyano-2-(3̸...)
Affinity DataIC50: 10nMAssay Description:The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM446452(US10669271, Example 5 | (S)-1-((7-cyano-2-(3′...)
Affinity DataIC50: 10nMAssay Description:The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM446470(US10669271, Example 23 | (S)-1-((7-cyano-2-(3̸...)
Affinity DataIC50: 10nMAssay Description:The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM446469(US10669271, Example 22 | (S)-1-((7-cyano-2-(3̸...)
Affinity DataIC50: 10nMAssay Description:The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM446465(US10669271, Example 18 | US10669271, Example 21 | ...)
Affinity DataIC50: 10nMAssay Description:U2OS/PD-L1 cells (DiscoveRx Corporation) were maintained in McCoy's 5A medium with addition of 10% FBS, 0.25 μg/ml Puromycin. After removing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM446450(US10669271, Example 3 | (S)-1-((7-cyano-2-(3′...)
Affinity DataIC50: 10nMAssay Description:U2OS/PD-L1 cells (DiscoveRx Corporation) were maintained in McCoy's 5A medium with addition of 10% FBS, 0.25 μg/ml Puromycin. After removing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM446476(US10669271, Example 29 | (R)-1-((2-(3′-(2-am...)
Affinity DataIC50: 10nMAssay Description:The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM446465(US10669271, Example 18 | US10669271, Example 21 | ...)
Affinity DataIC50: 10nMAssay Description:The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

LigandPNGBDBM446450(US10669271, Example 3 | (S)-1-((7-cyano-2-(3′...)
Affinity DataIC50: 10nMAssay Description:The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 94 total ) | Next | Last >>
Jump to: